| Bioactivity | Ravagalimab (ABBV-323) is a CD40 antagonist (EC50: 3.7 nM). Ravagalimab can be used for research of Crohn's disease[1]. |
| Invitro | Ravagalimab (0-100 nM，2 天) 抑制原代人 B 细胞上的 CD86 上调，EC50 为 0.6 nM[2]。 |
| Name | Ravagalimab |
| CAS | 2050816-56-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Argiriadi MA, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [2]. Yu X, et al. Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity. Cancer Cell. 2020 Jun 8;37(6):850-866.e7. |